Answers are grounded in this paper and cite their sources.
The therapeutic armamentarium for patients affected by advanced/inoperable hepatobiliary and pancreatic malignancies has significantly changed over the last decade. Key advancements include the integration of immunotherapy for hepatocellular carcinoma (HCC)1 and biliary tract cancers (BTC), and targeted therapies for BTC.2 Development of triplet chemotherapy and perioperative treatment is now well established in pancreatic cancer. A few very interesting studies in these areas were presented in Madrid during the European Society for Medical Oncology (ESMO) 2023 Annual Conference and are summarized below.
No takes yet. Share an insight, caveat, or question.
Fulgenzi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: